TRUBERZI Film-coated tablet Ref.[7577] Active ingredients: Eluxadoline

Source: European Medicines Agency (EU)  Revision Year: 2020  Publisher: Allergan Pharmaceuticals International Limited, Clonshaugh Business & Technology Park, Dublin 17, D17 E400, Ireland

Product name and form

Truberzi 75 mg film-coated tablets.

Truberzi 100 mg film-coated tablets.

Pharmaceutical Form

Truberzi 75 mg film-coated tablets: Modified capsule-shaped, pale yellow to light-tan film-coated tablet of approximately 7 mm x 17 mm, debossed with “FX75” on one side.

Truberzi 100 mg film-coated tablets: Modified capsule-shaped, pink-orange to peach film-coated tablet of approximately 8 mm x 19 mm, debossed with “FX100” on one side.

Qualitative and quantitative composition

Truberzi 75 mg film-coated tablets: Each film-coated tablet contains 75 mg of eluxadoline.

Truberzi 100 mg film-coated tablets: Each film-coated tablet contains 100 mg of eluxadoline.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Eluxadoline

Eluxadoline is a locally acting, mixed mu opioid receptor (μOR) agonist and delta opioid receptor (δOR) antagonist. Eluxadoline is also an agonist at the kappa opioid receptor (κOR). Eluxadoline has demonstrated efficacy in normalizing GI transit and defecation in several models of stress induced or post GI inflammation-altered GI function in animals.

List of Excipients

Silicified microcrystalline cellulose (E460)
Colloidal anhydrous silica (E551)
Crospovidone, type B (E1202)
Mannitol (E421)
Magnesium stearate (E572)
Polyvinyl alcohol (E1203)
Titanium dioxide (E171)
Macrogol 3350 (E1521)
Talc (E553b)
Iron oxide yellow (E172)
Iron oxide red (E172)

Pack sizes and marketing

PCTFE/PVC/Al-blister containing 14 film-coated tablets. Pack sizes of 28, 56 and a multipack containing 168 (3 packs of 56) film-coated tablets.

Not all pack sizes may be marketed.

Marketing authorization holder

Allergan Pharmaceuticals International Limited, Clonshaugh Business & Technology Park, Dublin 17, D17 E400, Ireland

Marketing authorization dates and numbers

EU/1/16/1126/001-006

Date of first authorisation: 19 September 2016

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.